No Data
No Data
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
Analyst Expectations For Incyte's Future
6 analysts have shared their evaluations of Incyte (NASDAQ:INCY) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recen
Express News | Cantor Fitzgerald Reiterates Neutral on Incyte
Incyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 — Cantor Fitzgerald Reiterates → Neutral 05/23/2024 -12.27% Deutsche Bank → $55 Initiates Cove
Research Alert: CFRA Keeps Buy View On Shares Of Incyte Corporation
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Following the solid rally seen Incyte Co
Executive VP & GM of North America Of Incyte Sold 63% Of Their Shares
Some Incyte Corporation (NASDAQ:INCY) shareholders may be a little concerned to see that the Executive VP & GM of North America, Barry Flannelly, recently sold a substantial US$1.1m worth of stock at
Elons Pube : Do you do option trading?
DouGieeOP Elons Pube: no options. just overnight trading explain 22nd and 23rd
Elons Pube DouGieeOP: What do you mean by explain 22nd and 23rd
DouGieeOP Elons Pube: sorry i means "which explains 22nd and 23rd"
Elons Pube DouGieeOP: Thanks